Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsaw

Rösler, Michael; Anand, R.; Cicin-Sain, A.; Gauthier, Serge; Agid, Yves; Dal‐Bianco, Peter; Stähelin, H.B.; D. Hartman, Richard; Gharabawi, M.; Bayer, Antony

doi:10.1136/bmj.318.7184.633

Public

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsaw

Published in BMJ • Mar 6, 1999

Authors:

Michael Rösler

R. Anand

A. Cicin-Sain

Abstract

OBJECTIVES: To assess the effects of rivastigmine on the core domains of Alzheimer's disease. DESIGN: Prospective, randomised, multicentre, double blind, placebo controlled, parallel group trial. Patients received either placebo, 1-4 mg/day (lower dose) rivastigmine, or 6-12 mg/day (higher dose) riv...

Subject

Rivastigmine

Placebo

Clinical Global Impression

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!